Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.

Anti-cancer drugs - 1 Jan 2011

Sylvester Robert K, Steen Preston, Tate John M, Mehta Minesh, Petrich Ryan J, Berg Alexander, Kolesar Jill

Abstract excerpt

Genotyping of putative determinants of temozolomide (TMZ)-induced life-threatening bone marrow suppression was performed in two patients with glioma treated with adjuvant TMZ and radiation therapy. DNA was extracted from the patients' mononuclear cells and genotyping of O-methylguanine-DNA-methyltransferase (MGMT), multidrug resistance (MDR1; also known as ABCB1), NQO1, and GSTP1 genes and analysis for the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dacarbazine

Share to Glutathione S-Transferase pi

Share to NAD(P)H Dehydrogenase (Quinone)

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to Patients

Share to Temozolomide

Source

Identifiers

PMID: 20938339
DOI: 10.1097/CAD.0b013e3283407e9f

Genes

MGMT
ABCB1
GSTP1
NQO1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Temozolomide-induced severe myelosuppression: analysis of clinically associated polymorphisms in two patients.PMID 20938339Read ↗

Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.Semantic proximity Read ↗

Clinical and genetic predictors of temozolomide-induced severe myelotoxicity in adult diffuse glioma: a case-control study.Semantic proximity Read ↗

Temozolomide-induced myelotoxicity and single nucleotide polymorphisms in the MGMT gene in patients with adult diffuse glioma: a single-institutional pharmacogenetic study.Semantic proximity Read ↗

Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.Semantic proximity Read ↗

MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.Semantic proximity Read ↗

Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.Semantic proximity Read ↗

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.Semantic proximity Read ↗

Functional germline variants in DNA damage repair pathways are associated with altered survival in adults with glioma treated with temozolomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.